Funder: National Institutes of Health (NIH)
Due Dates: February 16, 2026 (Forecasted)
Funding Amounts: R61 phase: up to 2 years; R33 phase: up to 3 years; number of awards expected: 5; award ceiling not specified
Summary: Supports translational research to advance laboratory findings into therapeutics for visual system diseases or disorders.
Key Information: Milestone-driven, bi-phasic mechanism (R61/R33); clinical trials not allowed; forecasted opportunity—dates subject to change.